Nsaid Safety | Skills Pool
Nsaid Safety NSAID comparison (meloxicam, carprofen, deracoxib, firocoxib, robenacoxib), species-specific dosing, GI ulceration risk factors, renal monitoring protocols, corticosteroid washout requirements, COX-1 vs. COX-2 selectivity.
Overview
Evidence-based NSAID selection, dosing by species, contraindication recognition, and safety monitoring protocols. Includes COX-1 vs. COX-2 selectivity comparison, renal/GI risk stratification, and drug interaction management.
When to Use
User prescribes NSAID or assesses drug safety for concurrent NSAID use
User needs NSAID selection, dosing verification, or renal/GI monitoring plan
Keywords: NSAID, meloxicam, carprofen, deracoxib, firocoxib, robenacoxib, GI ulcer, renal, COX, anti-inflammatory, contraindication, drug interaction
NSAID Comparison Table
Drug Species Dose Route Frequency COX Selectivity Comments Meloxicam Dog 0.1-0.2 mg/kg PO/IV/SC Daily COX-2 preferential Longer half-life (12-18h); IV/SC option; first-line many practices
npx skillvault add OpenVet-Projects/openvet-projects-vetclaw-skills-safety-nsaid-safety-skill-md
星标 7
更新时间 2026年3月18日
职业 Cat 0.1 mg/kg PO/SC/IV Daily COX-2 preferential CONTROVERSIAL dosing : 0.3-0.5 mg/kg q48h alternative; GI risk lower than dogs at low dose; renal monitoring mandatory
Rabbit 0.6-1 mg/kg PO/SC BID COX-2 preferential Limited data; anecdotal use; monitor renal/GI closely
Carprofen Dog 2-4 mg/kg PO/IV BID-TID COX-2 preferential (mild) Rapid GI absorption; shorter half-life (8 hours); hepatotoxicity rare but reported
Cat 1-2 mg/kg PO/IV BID COX-2 preferential (mild) Limited feline data; less commonly used in cats; GI ulceration risk higher than meloxicam
Deracoxib Dog 1-2 mg/kg PO Daily COX-2 selective Food-dependent absorption (give with food); 5-7 day max acute, 30 days chronic (FDA restriction)
Firocoxib Dog 5 mg/kg PO Daily COX-2 highly selective Equine label (5 mg/kg); less GI ulceration than carprofen; excellent for orthopedic pain; expensive
Horse 0.1 mg/kg IV/5 mg/kg PO PO/IV Daily COX-2 highly selective Superior to phenylbutazone in some studies; longer plasma half-life
Robenacoxib Dog/Cat 1-2 mg/kg SC/IV Daily × 4-10 days COX-2 selective Short-term use primarily; less renal effects at short durations; expensive; limited US availability
COX-1 vs. COX-2 Selectivity COX-1 Functions : Gastric mucosal protection (prostaglandins), platelet aggregation, renal hemodynamics, tissue homeostasis
Inhibition consequence : GI ulceration, platelet dysfunction, renal perfusion reduction COX-2 Functions : Inflammation, fever, pain; also renal and gastric roles in chronic settings
Selectivity advantage : Lower GI ulceration risk; some renal protective effects at lower doses Clinical Implication : COX-2 selective agents (meloxicam, firocoxib, deracoxib, robenacoxib) safer GI profiles than less-selective agents (carprofen) in short-term use; long-term use blunts selectivity advantage
GI Ulceration Risk Factors Intrinsic Risk (patient factors):
Age (geriatric >7 years; puppies/kittens immature mucosa)
Concurrent disease (inflammatory bowel disease, gastric ulcer history, neoplasia)
Hepatic/renal disease (reduced clearance, decreased perfusion)
Hypoproteinemia (<5.0 g/dL; reduced gastric mucosa protection)
Dehydration (reduced gastric blood flow)
NSAIDs increase risk 4-6× in dogs; cats lower baseline risk but elevation if predisposed
Extrinsic Risk (drug factors):
High NSAID dose
Prolonged duration (risk increases after 2-4 weeks)
Concurrent corticosteroid use (synergistic ulceration risk; contraindicated )
Concurrent anticoagulant (inhibited platelet aggregation)
Multiple NSAIDs (avoid combining even "safer" pairs)
Gastroduodenal Complications :
Grade 1 : Gastric mucosal erythema, no erosion; asymptomaticGrade 2 : Erosions <3 mm; vomiting possibleGrade 3-4 : Ulcers >3 mm, perforation risk; hematemesis, melena, severe pain
Renal Monitoring Protocol Baseline Assessment (before NSAID initiation):
Serum creatinine, BUN, urine specific gravity (USG)
Contraindicate NSAID if: Cr >1.8 mg/dL (dogs), >1.6 mg/dL (cats); pre-existing renal disease; dehydration present
Recheck BUN/creatinine at 7-10 days if new NSAID (acute phase kidney injury risk peaks early)
Repeat at 2-4 weeks if continuing >2 weeks duration
For chronic NSAIDs (months+): Check q3-6 months
Decrease renal perfusion (COX-2 inhibition reduces renal vasodilation)
Acute kidney injury risk in hypovolemic/dehydrated states
Chronic risk: Progressive glomerulosclerosis with prolonged high-dose use
Discontinuation Indications :
Creatinine increase >0.5 mg/dL from baseline
BUN >40 mg/dL without other explanation
Evidence of acute kidney injury (azotemia + clinical signs)
Oliguria/polyuria development
Species-Specific Dosing and Considerations
Dogs
Standard dose : Meloxicam 0.1-0.2 mg/kg daily; carprofen 2-4 mg/kg BIDGeriatric/renal disease : Reduce to minimum effective dose; meloxicam 0.1 mg/kg daily preferred (less renal impact)Post-operative : Start pre-operatively (pre-emptive analgesia); continue 5-7 days minimumChronic orthopedic disease : Long-term meloxicam acceptable with monitoring; consider adjuvant agents (gabapentin, joint supplements) to minimize NSAID requirements
Cats
Meloxicam controversy : AAHA (2017) recommends 0.1 mg/kg daily (same as dogs); some practitioners prefer 0.3-0.5 mg/kg q48h
Rationale : Feline renal physiology; lower baseline GI risk; extrarenal NSAID metabolism; palatability of sustained dosingConservative approach : 0.1 mg/kg daily with renal monitoring remains safest evidence-based recommendation
GI risk : Cats more sensitive to severe GI ulceration than dogs despite lower overall baselineRenal monitoring : Mandatory (USG, BUN, creatinine baseline and q2-4 weeks)Chronic use : Short-term (acute pain, <2 weeks) preferred; long-term requires strong indication and close monitoring
Rabbits/Small Mammals
Meloxicam : 0.6-1 mg/kg PO/SC BID common dosing (limited species-specific data)GI stasis risk : Meloxicam may reduce appetite/motility; ensure adequate hydration and hay intakeCarprofen : Anecdotal use; minimal data; generally avoidedMonitoring : Renal monitoring less standardized; assess appetite, fecal output, hydration
Horses
Firocoxib : 5 mg/kg daily PO (approved label); superior to phenylbutazone (PBZ, older standard) in some pain modelsPhenylbutazone : Traditional (4.4 mg/kg daily max); longer-term GI ulceration risk; now second-lineMonitoring : Renal dysfunction less common in horses; GI ulceration still riskMaximum duration : 30 days typically recommended (extended use controversial)
Corticosteroid + NSAID Interaction Mechanism : Corticosteroids inhibit phospholipase A2 (blocks arachidonic acid release); NSAIDs inhibit COX; combined blockade → synergistic GI ulceration
Contraindication : Absolute: Do NOT combine systemic corticosteroid + NSAID concurrently
Washout period : Discontinue corticosteroid ≥1 week before initiating NSAID OR discontinue NSAID ≥1 week before corticosteroid Exception : Topical corticosteroids (ophthalmic, dermal) + systemic NSAID generally safe (minimal systemic absorption)
Alternative : Use NSAID + adjuvant analgesic (gabapentin, tramadol) instead of corticosteroid if possible
Drug Interactions and Contraindications NSAIDs + Anticoagulants (warfarin, apixaban): Increased bleeding risk; avoid if possible; if necessary, use lowest NSAID dose, monitor INR closely
NSAIDs + ACE Inhibitors (enalapril, lisinopril): Combined renal perfusion reduction; acceptable in euvolemic patients; contraindicated if dehydrated
NSAIDs + Diuretics : Reduced renal perfusion; monitor renal function closely; ensure adequate hydration
NSAIDs + Methotrexate : Reduced MTX clearance; potential toxicity; monitor closely
Absolute Contraindications :
Acute/chronic kidney disease (Cr >1.8 dogs, >1.6 cats without specialist guidance)
Severe hepatic disease
Active GI ulceration (confirmed or high suspicion)
Platelet dysfunction disorders
Concurrent corticosteroid (system non-topical)
Hypersensitivity/allergy history
GI Protection Strategies H2 Blockers (famotidine 0.5-1 mg/kg q12h):
Reduces gastric acid; modest ulceration prevention
Minimal evidence for routine prophylaxis in short-term NSAID use
Consider if: Geriatric, pre-existing GI disease, high-risk NSAID choice
Proton Pump Inhibitors (omeprazole 0.5-1 mg/kg q24h):
Superior acid suppression to H2 blockers
Limited evidence for routine prophylaxis short-term
Consider if: High-risk patient, previous NSAID intolerance, chronic NSAID use
Misoprostol (2-5 mcg/kg q6-8h): Prostaglandin analog; promotes gastric mucosa protection
Reduced diarrhea (side effect) in cats; avoid if GI dysmotility risk
Limited practical use due to dosing frequency
Evidence : Routine GI protection not recommended for short-term (<2 weeks) NSAID use in low-risk patients; consider for high-risk or chronic use
Monitoring and Patient Selection Workflow
Assess renal function baseline : Serum creatinine, BUN, USG; exclude if abnormalAssess GI risk : History of ulceration, concurrent medications, age, dehydration statusSelect appropriate NSAID : COX-2 selective (meloxicam, firocoxib) preferred over less-selective agents; meloxicam for cats with renal monitoringVerify no corticosteroid within 1 week : Washout period essentialEstablish monitoring plan : Recheck creatinine/BUN at 7-10 days if new prescription; q2-4 weeks if chronic; assess appetite/vomiting at each visitEducate owner : Signs of GI ulceration (vomiting, melena, anorexia); signs of renal disease (polyuria, polydipsia, lethargy); importance of monitoring
Limitations
Baseline renal assessment : Many animals have subclinical renal disease (eGFR reduced despite normal creatinine); urine protein assessment (UP:C) not routine in screeningNSAID selectivity : Clinical significance of COX-1 vs. COX-2 selectivity debated; all NSAIDs carry GI/renal risk at higher doses or longer durationFeline meloxicam dosing : Significant controversy; "safe" dose remains undefined; individual variation largeGI protection efficacy : Limited high-quality evidence for routine prophylaxis; many protection strategies add cost without proven benefit in short-term useChronic NSAID use : Long-term safety data limited; adjuvant agents (gabapentin, joint supplements) may reduce NSAID requirements but evidence variableReferral : Complex polypharmacy, unexplained renal elevation during NSAID therapy, or refractory pain → internist/pain specialist consideration When to Use
计算化学
Drug Discovery Pharmaceutical research assistant for drug discovery workflows. Search bioactive compounds on ChEMBL, calculate drug-likeness (Lipinski Ro5, QED, TPSA, synthetic accessibility), look up drug-drug interactions via OpenFDA, interpret ADMET profiles, and assist with lead optimization. Use for medicinal chemistry questions, molecule property analysis, clinical pharmacology, and open-science drug research.